• About Us
  • Overview
  • Strategy
  • Management >
    • Board of Directors
    • Senior Management
  • Scientific Advisory Board
  • Job Opportunities
• Clinical Trials
  • Overview
• Products
  • Advanced Pipeline >
    • TroVax^®
    • ProSavin^®
    • Hi-8 MEL^®
    • MetXia^®
    • RetinoStat^®
  • Early-stage Pipeline >
    • StarGen^®
    • MoNuDin^®
    • SMN-1G
    • Innurex^®
    • ReQuinate^®
    • ImmStat^®
    • EndoAngio-GT
    • Targeted Antibody
• Technology
  • Gene Delivery Technologies
  • Gene Discovery and Target Validation
  • Antibody Delivery
  • Hypoxia Response Element
• Collaborations
  • Corporate Partnerships
  • Technology Licence Agreements
  • Scientific Collaborations and Advisors
• Investors
  • Financing History
  • Accounts
  • Share Price
  • Presentation >
    • Interim Results August 2008
    • Annual General Meeting May 2008
    • Annual Results March 2007
  • Web Casts
  • Announcements
  • Shareholder Meetings
  • Contact
• News
  • Announcements
  • Events
  • Media Coverage
• Contact Us
  • UK >
    • Contacts
    • Directions
    • Map
  • USA >
    • Contacts
    • Directions
    • Map

Oxford BioMedica’s Board of Directors have the depth of experience in research, development, intellectual property management, manufacturing, business development and finance needed to effectively manage a leading-edge biotechnology company in today’s challenging environment.
Alan Kingsman	Chairman
John Dawson	Chief Executive Officer
Andrew Wood	Chief Financial Officer
Nick Woolf	Chief Business Officer
Stuart Naylor	Chief Scientific Officer
Peter Nolan	Senior Vice President, Commercial Development
Nick Rodgers	Deputy Chairman
Mark Berninger	Non-Executive Director
Alex Lewis	Non-Executive Director
Terms of Reference of the Remuneration Committee Terms of Reference of the Audit Committee

Website by College Hill - Life Sciences